24.08.2023

To
The Selection Committee Members
Sun Pharma Science Foundation

Dear Sir/Madam,

I do hereby declare that the research work for which I am claiming Sun Pharma Award has not given me any award in the past. My award claim is based on two very recent senior authored papers (***Nature Communications, 2022 and Redox Biology, 2023***) and one patent (***PCT/IN2021/051182***) in which we initiated IND studies. Here are the details of contributions for each paper/patent:

1. A. Verma, A. Singh, M.P. Singh, M.A. Nengroo, K.K. Saini, S.R. Satrusal, M.A. Khan, P. Chaturvedi, A. Sinha, S. Meena, A.K. Singh, **D. Datta***, EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis, ***Nat Commun, 13 (2022) 7344. (JIF:17.69) (*Corresponding author)***

All the authors enlisted above belong to Datta lab only and complete data were generated in CSIR-CDRI from inception to final execution. Contribution details as documented in published article are as follows:
Author Contribution: A.V. was involved with study designing, performed experiments, and wrote the draft paper. AS helped in carrying out in vivo studies. M.P.S. performed bioinformatic analysis. M.A.N., K.K.S., A.B.S., P.C., S.R.S., M.A.K., S.M., and A.K.S. provided active support for carrying out various in vitro and in vivo experiments. ***D.D. conceived the idea, designed experiments, analyzed data, wrote the paper, and provided overall supervision.*** All authors read and approved the final paper.

2. K.K. Saini, P. Chaturvedi, A. Sinha, M.P. Singh, M.A. Khan, A. Verma, M.A. Nengroo, S.R. Satrusal, S. Meena, A. Singh, S. Srivastava, J. Sarkar, **D. Datta*,** Loss of PERK function promotes ferroptosis by downregulating SLC7A11 (System Xc^-) in colorectal cancer, ***Redox Biology, 65, (2023) 102833. (JIF:11.4) (*Corresponding author)***
Contribution details as documented in published article are as follows:
Author Contribution: KKS was involved in study designing, performed experiments and wrote the draft manuscript. MPS performed bioinformatic analysis. PC, ABS, MAK AV, MAN, SRS, SM, and AS helped in carrying out in vitro and in vivo studies. SS provided support for patient sample data generation. JS helped in animal maintenance and experimentation. ***DD conceived the idea, designed experiments, analysed data, wrote the manuscript and provided overall supervision.*** All authors read and approved the final manuscript.

3. WO2022130411 - Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof, Publication Date: 23.06.2022
Contributors Name: Haq W, Ali R, Singh A, Nengroo MA, Katekar R, Singh G, Vaishnav J, Afsar M, Singh M, Rath SK, Koley D, Mishra DP, Ramachandran R, Ampapathi RS, Gayen JR, **Datta D.**
Contribution Details: Haq W, Ali R, and Koley D are involved in chemical synthesis, Singh G, Vaishnav J Afsar M, Ramachandran R, and Ampapathi RS are involved in target binding, Singh M and Mishra DP performed screening in leukemic cell, Katekar R and Gayen JR, did PK analysis, Rath SK involved in Tox studies, Singh A, Nengroo MA, belong to Datta lab and involved in biological evaluation of the molecule. ***DD supervised preclinical in-vitro and in-vivo efficacy assessment of the molecule and led the whole program to make it an IND candidate.***

Thanking you for your kind consideration. Look forward to your favourable response.

Sincerely,
Dipak Datta 24/08/2023
Dipak

Dipak Datta, Ph.D.
Senior Principal Scientist & Head.
Cancer Biology Division
CSIR-Central Drug Research Institute
Lucknow, India
दीपक दत्ता, पी.एच.डी.
वरिष्ठ प्रधान वैज्ञानिक एवं प्रभागाध्यक्ष
कैंसर जीवविज्ञान प्रभाग
सी.एस.आई.आर.–केन्द्रीय औषधि अनुसंधान संस्थान
लखनऊ, भारत